Actively Recruiting
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
Led by AstraZeneca · Updated on 2026-05-01
110
Participants Needed
9
Research Sites
118 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
ARES is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who have initiated tezepelumab (no more than 4 weeks before inclusion) for treatment of CRSwNP (with or without comorbid asthma).
CONDITIONS
Official Title
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participants aged 18 years or older at the time of signing the informed consent form.
- Diagnosis of chronic rhinosinusitis with nasal polyps established for at least 52 weeks before starting tezepelumab.
- Availability of medical records for at least 52 weeks before tezepelumab initiation, including history of systemic corticosteroid use or nasal polyp surgery.
- Treatment with tezepelumab prescribed and started within 4 weeks before enrollment.
- Severity of CRSwNP consistent with surgery need, defined by total nasal polyp score of 5 or higher at enrollment.
- Nasal blockage score of 3 or higher as part of the SNOT-22 questionnaire at enrollment.
- Total SNOT-22 score of 30 or higher at enrollment or within 12 weeks before enrollment.
- Currently receiving care from a specialist physician at the study site.
- Signed and dated written informed consent provided.
- Ability to read, understand, and complete the required questionnaires.
You will not qualify if you...
- Any contraindication to tezepelumab according to approved product information or investigator opinion.
- Use of other biologic drugs for CRSwNP or asthma since starting tezepelumab, except stable allergen immunotherapy.
- Participation in another observational study that may affect assessments or in an interventional clinical trial within the last 3 months.
- Pregnancy or lactation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Research Site
Kazan', Russia
Actively Recruiting
2
Research Site
Krasnoyarsk, Russia
Not Yet Recruiting
3
Research Site
Moscow, Russia
Actively Recruiting
4
Research Site
Rostov-on-Don, Russia
Actively Recruiting
5
Research Site
Ryazan, Russia
Actively Recruiting
6
Research Site
Saint-Petesburg, Russia
Actively Recruiting
7
Research Site
Saint-Petesburg, Russia
Not Yet Recruiting
8
Research Site
Ulyanovsk, Russia
Not Yet Recruiting
9
Research Site
Yekaterinburg, Russia
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here